Retatrutide

Retatrutide (LY3437943) is an investigational peptide-based triple-agonist targeting the GLP-1, GIP, and glucagon receptors, used strictly in research settings to study metabolic regulation, energy balance, and potential therapeutic pathways for obesity and related metabolic disorders; it is not an approved drug for clinical treatment, and its safety, efficacy, and appropriate dosing in humans outside controlled trials have not been established or validated.